Operating expenses for Westlake Village-based Sienna Biopharmaceuticals more than doubled for the first quarter to $18.5 million as it launched a third product into clinical trials. The pre-revenue company said net loss came to $17.1 million, or 85 cents per share, and it burned through $14.5 million for the quarter ended March 31, leaving it…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
